Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:9300706rdf:typepubmed:Citationlld:pubmed
pubmed-article:9300706lifeskim:mentionsumls-concept:C0039195lld:lifeskim
pubmed-article:9300706lifeskim:mentionsumls-concept:C1704632lld:lifeskim
pubmed-article:9300706lifeskim:mentionsumls-concept:C0871261lld:lifeskim
pubmed-article:9300706lifeskim:mentionsumls-concept:C0019409lld:lifeskim
pubmed-article:9300706lifeskim:mentionsumls-concept:C2911692lld:lifeskim
pubmed-article:9300706lifeskim:mentionsumls-concept:C1706817lld:lifeskim
pubmed-article:9300706lifeskim:mentionsumls-concept:C0205460lld:lifeskim
pubmed-article:9300706pubmed:issue6lld:pubmed
pubmed-article:9300706pubmed:dateCreated1997-10-8lld:pubmed
pubmed-article:9300706pubmed:abstractTextTo better understand how Ag density influences the various biologic responses of CTL, we analyzed lysis and, at the single cell level, cytokine production by a panel of melanoma-specific CTL clones. Titration experiments done with peptide-pulsed TAP-deficient T2 cells indicated that: 1) Ag density affects both the fraction of responding cells and the amount of cytokine secreted by each cell. 2) Different responses have a relative Ag requirement that may vary between clones. Lysis and secretion of IFN-gamma, and for most clones' secretion of TNF-alpha, required lower Ag densities, by one or two logs, than IL-2 and granulocyte-macrophage CSF secretion. 3) In a significant fraction of IFN-gamma-secreting cells, IL-2 production is not induced. 4) A large fraction of cloned cells is refractory to lymphokine gene activation for about 2 wk after previous stimulation. Together these data indicate that CTL biologic responses are controlled by variable Ag thresholds and by additional parameters affecting activation requirements of each cell. A similar heterogeneity of cytokine responses was observed to Ag endogenously presented by melanoma cells. As a consequence, most melanoma lines, including those with the highest Ag expression, could trigger only low CTL fractions to secrete IL-2 and, also for most clones, granulocyte-macrophage CSF. This may be an important component of the inefficiency of specific CTL in cancer patients.lld:pubmed
pubmed-article:9300706pubmed:languageenglld:pubmed
pubmed-article:9300706pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9300706pubmed:citationSubsetAIMlld:pubmed
pubmed-article:9300706pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9300706pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9300706pubmed:statusMEDLINElld:pubmed
pubmed-article:9300706pubmed:monthSeplld:pubmed
pubmed-article:9300706pubmed:issn0022-1767lld:pubmed
pubmed-article:9300706pubmed:authorpubmed-author:JotereauFFlld:pubmed
pubmed-article:9300706pubmed:authorpubmed-author:DiezEElld:pubmed
pubmed-article:9300706pubmed:authorpubmed-author:GervoisNNlld:pubmed
pubmed-article:9300706pubmed:authorpubmed-author:Le DréanEElld:pubmed
pubmed-article:9300706pubmed:authorpubmed-author:Le GuinerSSlld:pubmed
pubmed-article:9300706pubmed:authorpubmed-author:FonteneauJ...lld:pubmed
pubmed-article:9300706pubmed:issnTypePrintlld:pubmed
pubmed-article:9300706pubmed:day15lld:pubmed
pubmed-article:9300706pubmed:volume159lld:pubmed
pubmed-article:9300706pubmed:ownerNLMlld:pubmed
pubmed-article:9300706pubmed:authorsCompleteYlld:pubmed
pubmed-article:9300706pubmed:pagination2831-9lld:pubmed
pubmed-article:9300706pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:9300706pubmed:meshHeadingpubmed-meshheading:9300706-...lld:pubmed
pubmed-article:9300706pubmed:meshHeadingpubmed-meshheading:9300706-...lld:pubmed
pubmed-article:9300706pubmed:meshHeadingpubmed-meshheading:9300706-...lld:pubmed
pubmed-article:9300706pubmed:meshHeadingpubmed-meshheading:9300706-...lld:pubmed
pubmed-article:9300706pubmed:meshHeadingpubmed-meshheading:9300706-...lld:pubmed
pubmed-article:9300706pubmed:meshHeadingpubmed-meshheading:9300706-...lld:pubmed
pubmed-article:9300706pubmed:meshHeadingpubmed-meshheading:9300706-...lld:pubmed
pubmed-article:9300706pubmed:meshHeadingpubmed-meshheading:9300706-...lld:pubmed
pubmed-article:9300706pubmed:meshHeadingpubmed-meshheading:9300706-...lld:pubmed
pubmed-article:9300706pubmed:meshHeadingpubmed-meshheading:9300706-...lld:pubmed
pubmed-article:9300706pubmed:meshHeadingpubmed-meshheading:9300706-...lld:pubmed
pubmed-article:9300706pubmed:year1997lld:pubmed
pubmed-article:9300706pubmed:articleTitleHeterogeneity of biologic responses of melanoma-specific CTL.lld:pubmed
pubmed-article:9300706pubmed:affiliationINSERM Unit 463 and Faculté des Sciences de Nantes, France.lld:pubmed
pubmed-article:9300706pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:9300706pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9300706lld:pubmed